top of page

Poster 37


Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients With Moderate to Severe Plaque Psoriasis Who Had Inadequate Responses to Apremilast at Week 24 in the Phase 3 POETYK PSO-1 and PSO-2 Trials

Authors: April W Armstrong, Richard B Warren, Howard Sofen, Lynda Spelman, Craig Leonardi, Subhashis Banerjee, Tao Wang, John Throup, Elizabeth Colston, Andrew Napoli, Alexa B Kimball


POSTER 37

< PREVIOUS POSTER NEXT POSTER >

14 views

QUESTIONS, COMMENTS, & SURVEY

Please Rate This PosterPoorFairGoodVery goodExcellentPlease Rate This Poster
Thank you for submitting your feedback!

Search by Poster Number

Topics_Poster_Sq_10.jpg
Topics_Poster_Sq_11.jpg
Topics_Poster_Sq_12.jpg
Topics_Poster_Sq_13.jpg
Topics_Poster_Sq_14.jpg
Topics_Poster_Sq_15.jpg
Topics_Poster_Sq_16.jpg
bottom of page